BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
about
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineLack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastasesCombined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2KDrug therapy for hereditary cancersRevealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.Modeling the Etiology of p53-mutated Cancer Cells.BRCA1 and BRCA2: different roles in a common pathway of genome protection.Clinical outcomes based on multigene profiling in metastatic breast cancer patientsImplications of genomic instability in the diagnosis and treatment of breast cancer.Impact of hyperhomocysteinemia on breast cancer initiation and progression: epigenetic perspective.Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Novel approaches to treatment of leiomyosarcomas.
P2860
Q28071541-47CDBF6C-4ACB-4CBA-95F3-DB094FAC09CEQ28072204-50DEBECD-66C9-4A0D-B824-28249E5B55E3Q33988970-05CF44B7-A76E-44BF-9339-B0F6489E83D7Q34880928-69A7E528-7181-4EC8-942C-D9430D9BEDC9Q35208929-7F87E70A-6599-4062-9F22-C2886FB4A8B8Q35593154-85DA6FA2-9CEC-4653-9904-FA4615315BF8Q35993095-FD974054-26DE-42F2-8C52-EBF94C8A5C03Q36195450-BA50E2F0-80D8-499F-9291-1538FB60CD8CQ36385670-D0CEEB53-7A86-4BF8-81DA-99CA29C61917Q36702175-38A945CF-B117-4341-9D3D-292D12E4AA8BQ36876179-E18A2B7D-1596-4BB5-B1DB-7C993A023C4BQ37149848-5182DFAE-A25C-41E7-80B1-B2BDE58ABB50Q37718221-FCCBA921-58EB-42CA-9498-FD6195C4D10EQ37872301-7C9FC672-56E3-4247-88D8-9854801121E5Q39112249-35C2406F-10BB-4B48-ACA6-D4B7EF549C77Q40656600-BFE49834-D0FF-4EB5-A0EA-21A2FDBB9722Q42517340-BDF6D9C6-5480-4E84-8BC3-34AC1A7EA9CFQ54595774-BAA687DD-C52B-4E01-9012-90769A6DCB92
P2860
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@ast
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@en
type
label
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@ast
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@en
prefLabel
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@ast
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@en
P2093
P2860
P50
P356
P1433
P1476
BRCA1-mutated and basal-like b ...... ein truncating TP53 mutations.
@en
P2093
Arno Velds
Henne Holstege
Hugo M Horlings
Jos Jonkers
Petra M Nederlof
P2860
P2888
P356
10.1186/1471-2407-10-654
P407
P577
2010-11-30T00:00:00Z
P5875
P6179
1035709516